QuidelOrtho Launches Certified Analyzer Program

PR Newswire

Initiative to expand testing access to underserved U.S. communities

SAN DIEGO
, Aug. 13, 2025 /PRNewswire/ — QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost.

“Our mission is rooted in equipping our customers so they can deliver diagnostic excellence to patients,” said Audra Jones, Senior Vice President, North America, QuidelOrtho. “By repurposing and rigorously certifying high-performing analyzers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities.”

Each analyzer in the program undergoes a robust, multi-point certification process at QuidelOrtho’s Rochester facility, including over 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. These analyzers undergo a comprehensive certification process to align with QuidelOrtho’s established quality and performance criteria and include a 12-month warranty on service and support.

The program features certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System. The VITROS platforms are designed to support community labs running general chemistries, immunoassay tests and drugs of abuse screening.

“We’re proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction,” added Jones. “This program isn’t just about affordability; it’s designed to improve accessibility and access of diagnostic solutions for healthcare providers in underserved communities.”

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.

Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

[email protected]

Media Contact:

D. Nikki Wheeler

Senior Director, Corporate Communications

[email protected]